Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEIPP24 LRPAP1 vaccine dose-escalation study in advanced NSCLC
NL-OMON51164Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of TEIPP24 and pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Erasmus MC. Started Sep 2021; status: completed.
02
Drugs
TEIPP24pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON51164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51164.